Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breast Cancer: Improving the Odds

Executive Summary

Breast cancer is the most common type of female cancer and the number two cancer killer in US women. Treatment options continue to expand and researchers are making steady advancements in cancer detection that they hope will one day enable most breast cancer cases to be diagnosed an an early, very curable stage.

You may also be interested in...



New Frontiers in Breast Cancer Research, Part I: Advances in Imaging and Diagnosis

After years of working for a "cure" for breast cancer, researchers have come to realize the enormity of the task. Although therapeutic advances are making it possible for women with advanced breast cancer to live longer, more comfortable lives, scientists still have a long way to go before they fully understand this complex disease. At this year's Society of Surgical Oncology's annual Cancer Symposium, researchers zeroed in on several key areas that could eventually unlock new methods of controlling, and possibly eliminating, this all too pervasive threat.

Breast Cancer: The Evolution in Breast Biopsy, Surgery, and Brachytherapy

Advances in breast cancer screening are making earlier detection the norm, but biopsy devices are progressing as well. Emerging technologies, along with a number of new oncolytic drugs, will add add to the growing treatment armamentarium for breast cancer.

Breast Cancer: The Evolution in Breast Biopsy, Surgery, and Brachytherapy

Advances in breast cancer screening are making earlier detection the norm, but biopsy devices are progressing as well. Emerging technologies, along with a number of new oncolytic drugs, will add add to the growing treatment armamentarium for breast cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035077

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel